These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23466360)

  • 1. An MRI-based dose--reponse analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial.
    Register SP; Kudchadker RJ; Levy LB; Swanson DA; Pugh TJ; Bruno TL; Frank SJ
    Brachytherapy; 2013; 12(3):210-6. PubMed ID: 23466360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
    Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer.
    Contreras JA; Wilder RB; Mellon EA; Strom TJ; Fernandez DC; Biagioli MC
    Int Braz J Urol; 2015; 41(1):40-5. PubMed ID: 25928509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
    Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
    Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.
    Hathout L; Folkert MR; Kollmeier MA; Yamada Y; Cohen GN; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):312-9. PubMed ID: 25304791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study.
    Veccia A; Caffo O; Fellin G; Mussari S; Ziglio F; Maines F; Tomio L; Galligioni E
    Radiat Oncol; 2015 Jun; 10():130. PubMed ID: 26054532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
    Kollmeier MA; Stock RG; Cesaretti J; Stone NN
    J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life.
    Sanmamed N; Chung P; Berlin A; Adleman J; Borg J; Lao B; Ghai S; Weersink R; Simeonov A; Rink A; Menard C; Helou J
    Brachytherapy; 2019; 18(4):477-483. PubMed ID: 31109872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving prostate brachytherapy quality assurance with MRI-CT fusion-based sector analysis in a phase II prospective trial of men with intermediate-risk prostate cancer.
    Brown AP; Pugh TJ; Swanson DA; Kudchadker RJ; Bruno TL; Christensen EN; van Vulpen M; Frank SJ
    Brachytherapy; 2013; 12(5):401-7. PubMed ID: 23380383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
    Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer.
    Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Nussen S; Eble MJ
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):83-9. PubMed ID: 17855010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy.
    Boyce-Fappiano D; Bathala TK; Ye R; Pasalic D; Gjyshi O; Pezzi TA; Noticewala SS; McGinnis GJ; Maroongroge S; Kuban DA; Nguyen QN; McGuire SE; Hoffman KE; Choi S; Tang C; Kudchadker RJ; Frank SJ
    Brachytherapy; 2020; 19(5):574-583. PubMed ID: 32682778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interobserver variability of 3.0-tesla and 1.5-tesla magnetic resonance imaging/computed tomography fusion image-based post-implant dosimetry of prostate brachytherapy.
    Watanabe K; Katayama N; Katsui K; Matsushita T; Takamoto A; Ihara H; Nasu Y; Takemoto M; Kuroda M; Kanazawa S
    J Radiat Res; 2019 Jul; 60(4):483-489. PubMed ID: 31083713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a relation between the radiation dose to the different sub-segments of the lower urinary tract and urinary morbidity after brachytherapy of the prostate with I-125 seeds?
    Steggerda MJ; Witteveen T; van den Boom F; Moonen LM
    Radiother Oncol; 2013 Nov; 109(2):251-5. PubMed ID: 24060176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-grade toxicity after conformal radiation therapy for prostate cancer--impact of bladder volume.
    Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Eble MJ
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):835-41. PubMed ID: 16289911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term urinary quality of life after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):454-61. PubMed ID: 12738320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between high and low source activity seeds for I-125 permanent seed prostate brachytherapy.
    Masucci GL; Donath D; Tétreault-Laflamme A; Carrier JF; Hervieux Y; Larouche RX; Bahary JP; Taussky D
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):781-6. PubMed ID: 20171808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of the relation between physical characteristics of prostate I-125 seed implants and lower urinary tract symptoms: bladder hotspot dose and prostate size are significant predictors.
    Steggerda MJ; van der Poel HG; Moonen LM
    Radiother Oncol; 2008 Jul; 88(1):108-14. PubMed ID: 18039548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.